Ascendis Health Ltd - Public Comps and Valuation Multiples

Ascendis Health Ltd Overview

About Ascendis Health Ltd

Ascendis Health is a drug manufacturer that produces and distributes health products for the human, animal, and plant markets. It has a portfolio of brands and products and owns recognized trademarks in the pharmaceutical and consumer health markets. Ascendis Health has five operating segments: consumer health, pharma, medical, animal health, and biosciences. The pharma division is the contributor to revenue and is further divided into Pharma Africa, Remedica, and Farmalider. Pharma includes generic manufacturing and distribution and over-the-counter medicine manufacturing and distribution. The company’s revenue is split between South Africa and Europe and is diversified across currencies, markets, sales channels, and customer groups.

Founded

2008

HQ

Employees

3.2K+

Website

ascendishealth.com

Sectors

Biopharmaceuticals

Financials

Last FY Revenue $88.9M

Last FY EBITDA -$9.4M

EV

$28.1M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Ascendis Health Ltd Financials

See Ascendis Health Ltd valuation multiples based on analyst estimates

Ascendis Health Ltd P&L

In the most recent fiscal year, Ascendis Health Ltd reported revenue of $88.9M and EBITDA of -$9.4M.

Ascendis Health Ltd expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Ascendis Health Ltd valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$88.9M	XXX	XXX	XXX
Gross Profit	XXX	$35.0M	XXX	XXX	XXX
Gross Margin	XXX	39%	XXX	XXX	XXX
EBITDA	XXX	-$9.4M	XXX	XXX	XXX
EBITDA Margin	XXX	-11%	XXX	XXX	XXX
EBIT	XXX	-$11.4M	XXX	XXX	XXX
EBIT Margin	XXX	-13%	XXX	XXX	XXX
Net Profit	XXX	$4.4M	XXX	XXX	XXX
Net Margin	XXX	5%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Ascendis Health Ltd including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Ascendis Health Ltd achieved $88.9M in revenue and -$9.4M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$88.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$35.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	39.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	-$9.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	-10.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	-$11.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	-12.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$4.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	4.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Ascendis Health Ltd

This financial data table provides comprehensive performance metrics for Ascendis Health Ltd, a company based in South Africa. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Ascendis Health Ltd reported $88.9M in total revenue.
Fiscal year EBITDA was -$9.4M.
The company maintained a gross profit margin of 39.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was -10.6%.
Net profit margin reached 4.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Ascendis Health Ltd. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Ascendis Health Ltd Stock Performance

Ascendis Health Ltd has current market cap of ZAR 538M (or $31.2M), and EV of ZAR 485M (or $28.1M).

Market Cap Evolution

Ascendis Health Ltd Stock Data

As of October 7, 2025, Ascendis Health Ltd's stock price is ZAR n/a (or $n/a).

See Ascendis Health Ltd trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$28.1M	$31.2M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Ascendis Health Ltd Valuation Multiples

Ascendis Health Ltd's trades at 0.3x EV/Revenue multiple, and -2.2x EV/EBITDA.

See valuation multiples for Ascendis Health Ltd and 15K+ public comps

Ascendis Health Ltd Financial Valuation Multiples

As of October 7, 2025, Ascendis Health Ltd has market cap of $31.2M and EV of $28.1M.

Equity research analysts estimate Ascendis Health Ltd's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ascendis Health Ltd's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$31.2M	XXX	$31.2M	XXX	XXX	XXX
EV (current)	$28.1M	XXX	$28.1M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	0.3x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-2.2x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-2.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	2.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-3.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ascendis Health Ltd Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Ascendis Health Ltd Margins & Growth Rates

Ascendis Health Ltd's revenue per employee in the last FY averaged $28K, while opex per employee averaged $15K for the same period.

Ascendis Health Ltd's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ascendis Health Ltd's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Ascendis Health Ltd and other 15K+ public comps

Ascendis Health Ltd Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-14%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$28K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$15K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	7%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	52%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial